Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients

European Journal of Clinical Pharmacology
Anna FerrariEmilio Sternieri

Abstract

The marketing of sumatriptan, a selective serotonin (5-HT) 1B/1D agonist, first of the class of triptans, has increased the therapeutic options for the treatment of migraine attacks. However, almost one third of patients in clinical trials fail to have headache relief after oral administration of sumatriptan. To evaluate whether the interindividual differences in the clinical response following oral administration of sumatriptan are due to differences in its pharmacokinetics. We compared the pharmacokinetics of sumatriptan after oral (100 mg) and subcutaneous (6 mg) administration in two age- and gender-matched groups: ten subjects (group A) with satisfactory response and ten (group B) with unsatisfactory response to oral sumatriptan. Patients were studied during headache-free intervals. Blood samples were taken serially from baseline to 360 min after oral administration and from baseline to 180 min after subcutaneous injection. Sumatriptan plasma concentrations were determined by high-performance liquid chromatography (HPLC) with an electrochemical detector. Following oral dosing, patients of group A absorbed sumatriptan significantly faster and achieved early plasma levels significantly higher than patients of group B. The sy...Continue Reading

References

Jan 1, 1991·European Neurology·P A FowlerN S Baber
Jun 15, 1991·JAMA : the Journal of the American Medical Association·R K CadyH Skaggs
Jan 1, 1995·European Journal of Clinical Pharmacology·L F LaceyP A Fowler
Nov 1, 1994·Clinical Pharmacokinetics·A K Scott
Sep 1, 1996·Headache·W H VisserM D Ferrari
Oct 31, 1998·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·C DuquesnoyE Fuseau
Jan 25, 2002·The New England Journal of Medicine·Peter J GoadsbyMichel D Ferrari
Dec 5, 2002·Current Medical Research and Opinion·C G Dahlöf
Apr 17, 2003·CNS Drugs·Alan M RapoportFred D Sheftell
May 29, 2003·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·A FerrariA Bertolini
Jan 6, 2004·Annals of Neurology·Rami BursteinMoshe Jakubowski
Jan 21, 2004·Current Pain and Headache Reports·Morris Levin
Jun 18, 2004·Current Medical Research and Opinion·Christine WallsJagdev Sidhu
Apr 20, 2005·Pain·Andrew H Ahn, Allan I Basbaum
May 25, 2005·Neurology·Rami Burstein, Moshe Jakubowski
May 27, 2005·The New England Journal of Medicine·Grant R Wilkinson
May 28, 2005·European Neurology·Peter J Goadsby
Dec 20, 2005·The Journal of Headache and Pain·Emilio SternieriAnna Ferrari
Jan 24, 2006·Cephalalgia : an International Journal of Headache·M LindeC Dahlöf
Mar 25, 2006·Cephalalgia : an International Journal of Headache·H J MaasO E Della Pasqua
Jul 13, 2006·Expert Review of Neurotherapeutics·Domenico D'AmicoGennaro Bussone
Aug 7, 2007·Expert Review of Neurotherapeutics·Piero BarbantiGiorgio Cruccu
Aug 8, 2007·Cephalalgia : an International Journal of Headache·R CadyF Skobieranda

❮ Previous
Next ❯

Citations

Sep 16, 2010·Current Treatment Options in Neurology·Alan K Cole, Michael J Marmura
May 21, 2010·Clinical Pharmacokinetics·Neal M DaviesJaime A Yáñez
Jun 22, 2013·Expert Opinion on Pharmacotherapy·Stephen D Silberstein, Dawn A Marcus
May 7, 2011·Drug Development and Industrial Pharmacy·Yukako ItoKanji Takada
Apr 11, 2013·Dental Clinics of North America·Jeffry R ShaeferAna Miriam Velly
May 5, 2011·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Graham LappinColin Garner
Sep 30, 2010·The Journal of Headache and Pain·Anna FerrariEmilio Sternieri
Sep 18, 2013·Headache·John F RothrockEdward F Smith
Sep 18, 2013·Headache·Per G DjupeslandRamy A Mahmoud
Mar 23, 2012·Headache·Florian Oberhardt, Anthony W Fox
Sep 28, 2012·Expert Opinion on Pharmacotherapy·Luana LionettoPaolo Martelletti
Dec 10, 2014·The Journal of Headache and Pain·Kentaro TokuokaYasuhiko Yamada
Sep 10, 2020·Cephalalgia : an International Journal of Headache·Peer Tfelt-Hansen, Hans-Christoph Diener
May 13, 2018·CNS Drugs·Anna FerrariCecilia Rustichelli
Aug 2, 2011·Chemical & Pharmaceutical Bulletin·Ravi SheshalaYusrida Darwis

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.